Wu Wen-Jie, An Pu-Gen, Zhong Yi-Wei, Hu Xiao, Wang Lin, Zhang Jie
Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.
National Center of Stomatology & National Clinical Research Center for Oral Diseases, Beijing, China.
Front Oncol. 2024 Jan 16;13:1273798. doi: 10.3389/fonc.2023.1273798. eCollection 2023.
The efficacy of treatments targeting recurrent or metastatic head and neck squamous cell carcinoma are unsatisfactory in practice for patients with a ECOG PS score ≥ 2. Thus, this study retrospectively evaluated the safety and efficacy of a programmed cell death 1 inhibitor (tislelizumab) combined with an epidermal growth factor receptor inhibitor (nimotuzumab) in treating patients with a PS score ≥ 2 who suffer from recurrent or metastatic oral squamous cell carcinoma (OSCC).
Fifteen patients were treated with tislelizumab (200 mg IV Q3W) and nimotuzumab (200 mg IV Q3W). Programmed cell death-ligand 1 (PD-L1) expression in tumor biopsies was assessed with immunohistochemistry. Whole-exome sequencing was used to evaluate treatment efficacy based on PD-L1 expression and gene mutation.
At a median follow-up of 9.6 months, median overall survival was 10.1 months, and median progression-free survival was 4.0 months. Overall response rate was 40%, with 6/15 patients achieving partial response. Eight patients exhibited nine adverse events, eight out of nine being grade 2 and the remaining being grade 3. Whole-exome sequencing showed that , and mutations were associated with patient prognosis.
Combination therapy involving tislelizumab plus nimotuzumab is a promising, low-toxicity treatment for recurrent or metastatic OSCC in patients with a PS score ≥ 2.
对于东部肿瘤协作组（ECOG）体力状况（PS）评分≥2的复发性或转移性头颈部鳞状细胞癌患者，目前针对该疾病的治疗在实际应用中的疗效并不理想。因此，本研究回顾性评估了程序性细胞死亡蛋白1抑制剂（替雷利珠单抗）联合表皮生长因子受体抑制剂（尼妥珠单抗）治疗PS评分≥2的复发性或转移性口腔鳞状细胞癌（OSCC）患者的安全性和疗效。
15例患者接受替雷利珠单抗（200mg静脉注射，每3周1次）和尼妥珠单抗（200mg静脉注射，每3周1次）治疗。采用免疫组织化学法评估肿瘤活检组织中程序性细胞死亡配体1（PD-L1）的表达。基于PD-L1表达和基因突变，使用全外显子测序来评估治疗效果。
中位随访9.6个月，中位总生存期为10.1个月，中位无进展生存期为4.0个月。总缓解率为40%，15例患者中有6例达到部分缓解。8例患者出现9次不良事件，其中9次中的8次为2级，其余为3级。全外显子测序显示， 以及 突变与患者预后相关。
替雷利珠单抗联合尼妥珠单抗的联合治疗方案对于PS评分≥2的复发性或转移性OSCC患者是一种有前景的、低毒性的治疗方法。
